Cerus Corporation (NASDAQ: CERS) announced that the U.S. Food and Drug Administration (FDA) has issued a revised draft guidance document ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

FBR Capital Reiterates Outperform on Cerus (CERS) Following FDA Approval March 16, 2016 10:18 AM Cerus Announces the Inclusion of Pathogen Reduction Technology in FDA’s Revised Guidance Document on Bacterial Safety Standards for PlateletsMarch 15, 2016 8:30 AM